Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic and Virologic Indices in Age-Differentiated HIV Cohorts
NCT00006144Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2000
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of lopinavir + ritonavir, emtricitabine and stavudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: CD4 cell count monitoring at Week 192 and HIV-1 RNA determinations at Week 192. Started Oct 2000; status: completed.
02
Drugs
lopinavir + ritonaviremtricitabinestavudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00006144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006144.